Summary of BAX/BAK hetero-oligomer formation in PBMNCs in response to obatoclax
| Infusion duration . | Dose level, mg/m2 . | Activated/informative . | Time to peak, h . | Time to resolution, h . |
|---|---|---|---|---|
| 1 hour | 3.5 | 1/1* | 1 h | 2 h |
| 5 | 0/1 | ND | ND | |
| 7 | 0/0 | ND | ND | |
| 10 | 1/1* | 3 h | > 4 h | |
| 14 | 3/4 | 1-2 h | > 4 h | |
| 3 hour | 20 | 1/2 | 2 h | 5 h |
| 28 | 3/4 | 2-5 h | > 5-8 h | |
| 40 | 3/3 | 3-4 h | 5-> 8 h | |
| Total | 12/16 |
| Infusion duration . | Dose level, mg/m2 . | Activated/informative . | Time to peak, h . | Time to resolution, h . |
|---|---|---|---|---|
| 1 hour | 3.5 | 1/1* | 1 h | 2 h |
| 5 | 0/1 | ND | ND | |
| 7 | 0/0 | ND | ND | |
| 10 | 1/1* | 3 h | > 4 h | |
| 14 | 3/4 | 1-2 h | > 4 h | |
| 3 hour | 20 | 1/2 | 2 h | 5 h |
| 28 | 3/4 | 2-5 h | > 5-8 h | |
| 40 | 3/3 | 3-4 h | 5-> 8 h | |
| Total | 12/16 |
ND indicates not documented.
Patient was dose-escalated. See Figure 2A.